MacroGenics 
Welcome,         Profile    Billing    Logout  
 20 Products   111 Diseases  20 Products   57 Trials   2463 News 
92 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tzield (teplizumab-mzwv) / Sanofi
PETITE-T1D, NCT05757713: Teplizumab in Pediatric Stage 2 Type 1 Diabetes

Active, not recruiting
4
20
US
teplizumab
Provention Bio, a Sanofi Company
Diabetes Mellitus, Type 1
08/26
08/26
PROTECT, NCT03875729 / 2018-004926-26: Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Completed
3
328
Europe, Canada, US, RoW
teplizumab, Placebo
Provention Bio, Inc.
Type 1 Diabetes Mellitus
05/23
05/23
2013-002248-98: Preventing Diabetes with an Antibody in Relatives at Risk for the Disease

Ongoing
2
170
Europe, RoW
Anti-CD3 mAb, MGA031, Infusion
TrialNet Coordinating Center, TrialNet Coordinating Center University of South Florida, TRAILNET COORDINATING CENTER AT THE UNIVERSITY OF SOUTH FLORIDA, National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Diabetes and Digestive and
Anti-CD3 monoclonal antibody is to be used for the prevention of type 1 diabetes mellitus in relatives at risk for developing the disease., Type 1 Diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT04270942: At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

Completed
2
6
US
teplizumab 1 mg/mL, PRV-031, Tzield
Provention Bio, a Sanofi Company
Diabetes Mellitus, Type 1
01/24
01/24
KIBOU-T1D, NCT06791291: Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

Recruiting
2
10
Japan
Teplizumab, SAR446681, TZIELD
Sanofi
Type 1 Diabetes Mellitus
03/28
03/28
2017-002871-24: A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-onset Type 1 Diabetes Mellitus (T1D)

Not yet recruiting
1/2
48
Europe
AG019, Teplizumab, Gastro-resistant capsule, hard, Solution for infusion
Intrexon T1D Partners, LLC (IT1D), IT1D
Recent-onset Type 1 Diabetes mellitus (T1D), Recent-onset Type 1 Diabetes mellitus (T1D), Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
GLP-TEP, NCT06338553: GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

Recruiting
1
24
US
Semaglutide (Rybelsus®), Placebo
Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes
03/27
03/27
NCT06481904: Registry for Stage 2 Type 1 Diabetes

Recruiting
N/A
200
US
TZIELD (teplizumab-mzwv)
Sanofi
Type 1 Diabetes
01/37
01/37
TEPLI-REAL, NCT06892002: Description of Patients With Type 1 Diabetes Treated With Teplizumab

Recruiting
N/A
100
US
Teplizumab
Sanofi
Type 1 Diabetes
07/25
07/25
NCT04598893 / 2020-002798-92: Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

Active, not recruiting
N/A
188
Europe, Canada, US, RoW
Teplizumab, Placebo
Provention Bio, a Sanofi Company
Diabetes Mellitus, Type 1
11/26
11/26
Margenza (margetuximab-cmkb) / TerSera Therap
2019-004699-21: Study of Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in HER2-Positive Gastric or Gastroesophageal Junction Cancer

Not yet recruiting
2/3
860
Europe, RoW
Margetuximab, INCMGA00012, MGD013, Trastuzumab, MGAH22, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Herceptin
MacroGenics, Inc., MACROGENICS, INC., MacroGenics, Inc., Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator),  Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator), Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator)
Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer, Gastric Cancer or Gastroesophageal Junction Cancer, Diseases [C] - Cancer [C04]
 
 
MAHOGANY, NCT04082364 / 2019-004699-21: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Checkmark Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Sep 2021 - Sep 2021: Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Checkmark Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Sep 2021 - Sep 2021: Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Hourglass Sep 2020 - Mar 2021 : Completion of enrollment of module A of MAHOGANY trial
More
Completed
2/3
82
Europe, US, RoW
margetuximab, MGAH22, Margenza®, Retifanlimab, MGA012, INCMGA00012, Tebotelimab, MGD013, Trastuzumab, Herceptin, Chemotherapy
MacroGenics, Zai Lab (Shanghai) Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
01/24
03/25
NCT04262804: A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Active, not recruiting
2
123
RoW
Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine), Chosen Chemotherapy (Vinorelbine ), Chosen Chemotherapy (Gemcitabine )
Zai Lab (Shanghai) Co., Ltd.
Breast Cancer Metastatic
09/21
12/23
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
10/24
07/27
NCT03219268: A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Checkmark Data from trial for DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for DLBCL at ASH 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Nov 2020 - Nov 2020: Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at ASCO 2020
More
Completed
1
277
Europe, US, RoW
tebotelimab 1 mg, MGD013, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab, MGAH22, Margenza
MacroGenics
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
02/23
02/23
PRV-3279 / Sanofi
PREVAIL-2, NCT05087628: PRV-3279-2a Trial in Systemic Lupus

Terminated
2
28
US, RoW
PRV-3279, SAR446811, Placebo
Provention Bio, a Sanofi Company
Systemic Lupus Erythematosus
05/24
06/24
enoblituzumab (MGA271) / MacroGenics
NCT02923180: Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Checkmark Safety and clinical activity from trial for prostate cancer at ASCO 2022
Jun 2022 - Jun 2022: Safety and clinical activity from trial for prostate cancer at ASCO 2022
Active, not recruiting
2
33
US
Enoblituzumab, MGA271
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics
Prostate Cancer
08/20
07/25
NCT05338580: Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Withdrawn
2
160
RoW
TJ271 Injection in Combination with Pembrolizumab
TJ Biopharma Co., Ltd.
First-line Non-small-cell Lung Cancer, First-line Urothelial Carcinoma, Second-line Urothelial Carcinoma, Second-line Melanoma
12/23
12/23
HEAT, NCT06014255: Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Recruiting
2
219
US
Enoblituzumab, MGA271, Standard of Care
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics
Prostate Cancer
03/29
03/29
NCT05708924: MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Terminated
1
1
US
FT538, Enoblituzumab, RES242, MGA271
Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI)
Cancer, Solid Tumor, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
08/24
08/24
flotetuzumab (MGD006) / MacroGenics
NCT04582864: Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Terminated
2
11
US
Flotetuzumab, MGD006, Donor lymphocyte infusion, DLI
Washington University School of Medicine, MacroGenics, National Cancer Institute (NCI)
Relapsed Acute Myeloid Leukemia
03/24
07/24
PEPN1812, NCT04158739: Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

Active, not recruiting
1
16
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Flotetuzumab, CD123 x CD3 DART Bi-Specific Antibody MGD006, CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody MGD006, MGD006, RES234, S80880
Children's Oncology Group, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
09/22
09/25
NCT04681105: Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Active, not recruiting
1
13
US
Acetaminophen, APAP, Paracetamol, Tylenol, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Diphenhydramine, FAR 90X2, PM 255, Probedryl, Rigidyl, S51, Syntedril, Flotetuzumab, CD123 x CD3 DART Bi-Specific Antibody MGD006, CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody MGD006, MGD006, RES234, S80880, Ibuprofen, (.+ -.)-p-Isobutylhydratropic acid, Advil, Motrin, p-Isobutylhydratropic acid, Ranitidine
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
05/26
05/26
NCT05506956: Post-transplant Flotetuzumab for AML

Completed
1
3
US
Flotetuzumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics, National Cancer Institute (NCI)
Leukemia, Myeloid, Acute
06/24
06/24
NCT04678466: Flotetuzumab Expanded Access Program

No Longer Available
N/A
NA
flotetuzumab, MGD006
MacroGenics
Acute Myeloid Leukemia, AML, AML, Adult Recurrent
 
 
Zynyz (retifanlimab-dlwr) / Incyte
POD1UM-304, NCT04205812 / 2019-003372-39: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Active, not recruiting
3
583
Europe, US, RoW
Retifanlimab, INCMGA00012, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel
Incyte Corporation, Zai Lab (Shanghai) Co., Ltd.
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
12/23
08/26
POD1UM-303, NCT04472429 / 2020-000826-24: Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (/InterAACT 2).

Hourglass Dec 2024 - Dec 2024 : sBLA submission for SCAC
Active, not recruiting
3
308
Europe, Japan, US, RoW
carboplatin, paclitaxel, retifanlimab, INCMGA00012
Incyte Corporation
Squamous Cell Carcinoma of the Anal Canal
04/24
03/26
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
01/26
06/26
2021-001181-38: Study on the treatment of patients with gastroesophageal cancer with chemotherapy and immunotherapy based on a non-functioning DNA mismatch repair mechanism in the tumour cells Onderzoek naar de behandeling van patiënten met maag-/slokdarmkanker met chemotherapie en immunotherapie op basis van een niet werkend DNA mismatch herstel mechanisme in de tumorcellen

Not yet recruiting
2
25
Europe
Retifanlimab, INCMGA00012, Solution for infusion
Academic Medical Center, Incyte
Gastroesophageal cancer Oesophagus- en maagcarcinoom, Gastroesophageal cancer Slokdarm- en maagkanker, Diseases [C] - Cancer [C04]
 
 
2020-002244-23: An Open-Label, Randomized, Phase 2, Study of Various Therapies for Participants With Muscle-Invasive bladder cancer who are not eligible for Cisplatin or Refuse Cisplatin Therapy and are having bladder removal (Optimus) Studio generale in aperto, randomizzato, di fase 2 per valutare varie terapie per partecipanti con carcinoma muscolo-invasivo della vescica che sono non idonei al cisplatino o rifiutano la terapia con cisplatino e si sottopongono rimozione della vescica (Optimus)

Not yet recruiting
2
45
Europe
Epacadostat, Retifanlimab, [INCB024360], [INCMGA00012], Tablet, Solution for infusion
INCYTE CORPORATION, Incyte Corporation
Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy Carcinoma uroteliale muscolo-invasivo della vescica non idoneo al cisplatino o che rifiuta la terapia con cisplatino e si sottopone a cistectomia radicale, Muscle-Invasive Bladder cancer Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and having bladder removal Carcinoma muscolo-invasivo della vescica non idoneo al cisplatino o che rifiuta la terapia con cisplatino e con rimozione della vescica, Diseases [C] - Cancer [C04]
 
 
2021-001085-37: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Chimiothérapie néo-adjuvante plus retifanlimab (INCMGA00012)chez les patients porteurs de sarcomes rétropéritoneaux sélectionnés : une étude randomisée de phase II.

Not yet recruiting
2
66
Europe
Retifanlimab, DOXORUBICIN, HOLOXAN, INCMGA00012, Solution for infusion, Powder for infusion, DOXORUBICIN, HOLOXAN (Ifosfamide)
Institut Bergonié, Incyte Biosciences International Sarl
retroperitoneal sarcomas sarcomes rétropéritonéaux, retroperitoneal sarcomas sarcomes rétropéritonéaux, Diseases [C] - Cancer [C04]
 
 
2018-002070-51: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Not yet recruiting
2
81
Europe, RoW
INCMGA00012, Solution for infusion
Incyte Corporation, Incyte Corporation
Squamous Carcinoma of the Anal Canal, Squamous Carcinoma of the Anal Canal, Diseases [C] - Cancer [C04]
 
 
POD1UM-201, NCT03599713 / 2018-001627-39: A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma

Checkmark Data from PODIUM-201 trial for metastatic merkel cell carcinoma at SITC 2021
Nov 2021 - Nov 2021: Data from PODIUM-201 trial for metastatic merkel cell carcinoma at SITC 2021
Checkmark Data from POD1UM-201 trial in Merkel cell carcinoma at ESMO 2020
Sep 2020 - Sep 2020: Data from POD1UM-201 trial in Merkel cell carcinoma at ESMO 2020
Completed
2
107
Europe, Canada, US, RoW
Retifanlimab, MGA012, INCMGA00012
Incyte Corporation
Metastatic Merkel Cell Carcinoma
01/22
06/24
2021-005775-39: A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Estudio an fase II, aleatorizado, doble ciego y multicéntrico de retifanlimab en combinación con INCAGN02385 e INCAGN02390 como tratamiento de primera línea en participantes con carcinoma escamoso de cabeza y cuello metastásico/recidivante .

Ongoing
2
162
Europe
Retifanlimab, INCMGA00012, INCAGN02385, INCAGN0290, Solution for infusion
Incyte Biosciences International Sarl, Incyte Biosciences International Sarl
In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN. En participantes con PD-L1 positivo y terapia sistémica R/M SCCHN sin tratamiento previo., In participants with biomarker positive and untreated advanced head and neck cancer En participantes con biomarcadores positivos y con cancer de cabeza y cuello avanzado no tratado., Diseases [C] - Cancer [C04]
 
 
NCT04225039: Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

Active, not recruiting
2
39
US
INCMGA00012, PD-1 inhibitor, PD1, INCAGN01876, Anti-GITR agonist, GITR, SRS, stereotactic radiosurgery, Brain surgery
University of Pennsylvania, Incyte Corporation
Glioblastoma
09/22
06/25
2022-000601-27: Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surgery in patients with operable Merkel cell carcinoma Studio volto a testare l’attività di un ciclo di chemio-immunoterapia con retifanlimab associato a platino-etoposide e seguito da chirurgia nei pazienti con carcinoma a cellule di Merkel operabile

Not yet recruiting
2
36
Europe
RETIFANLIMAB, CISPLATINO, carboplatino, etoposide, [INCMGA00012], [CISPLATINO], [carboplatino], [etoposide], Concentrate for solution for infusion
Fondazione GONO, Incyte Biosciences International, Fondazione GONO Onlus
The disease under clinical investigation is represented by resectable Merkel Cell Carcinoma (MCC), stage IIA-III (according to the AJCC staging system 8th edition). The study will include patients with a disease amenable for radical surgery as defined by local or institutional surgical practices, based on multidisciplinary team assessment La malattia oggetto di studio clinico è rappresentata dal tumore a cellule di Merkel (MCC) resecabile, stadiato clinicamente secondo il sistema di stadiazione AJCC, ottava edizione, come stadio IIA-III. Il protocollo arruolerà pazienti candidabili a trattamento chirurgico radicale secondo quanto definito dalla pratica clinica locale ed istituzionale, in seguito a valutazione in ambito multidisciplinare, Merkel cell carcinoma without metastases in other organs and surgically resectable Carcinoma a cellule di Merkel senza metastasi in altri organi e asportabile chirurgicamente, Diseases [C] - Cancer [C04]
 
 
ORPHEUS, NCT04231981 / 2019-001172-11: Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma

Completed
2
18
Europe
Retifanlimab, INCMGA0012
MedSIR, Incyte Biosciences International Sàrl
Penile Cancer
02/22
08/22
IRENE, NCT04445844: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, Study

Checkmark Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Dec 2021 - Dec 2021: Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Active, not recruiting
2
25
US
Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012
Mridula George, MD, Incyte Corporation, Oncolytics Biotech, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
06/25
06/25
NCT04949191 / 2021-002207-36: The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Terminated
2
10
Europe, Japan, US
Pemigatinib, INCB054828, Retifanlimab, INCMGA0012, Pembrolizumab
Incyte Corporation, Incyte Corporation
Advanced Malignancies
04/24
04/24
RHAPSODY, NCT04494009: PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy

Active, not recruiting
2
110
RoW
INCMGA00012
Asan Medical Center
Esophageal Cancer
12/25
12/26
NCT03532295: Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Hourglass Jan 2019 - Jan 2019 : P2 trial in recurrent gliomas
Active, not recruiting
2
51
US
Epacadostat, Bevacizumab, Avastin, Radiation therapy, Peripheral blood draw, Retifanlimab, INCMGA00012
Washington University School of Medicine, Incyte Corporation
Glioma, Glioblastoma
07/24
04/26
NCT05359692: INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Withdrawn
2
47
US
INCAGN01876, retifanlimab
Incyte Biosciences International Sàrl
Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
04/24
01/25
Optimus, NCT04586244 / 2020-002244-23: An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Terminated
2
30
Europe, US
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Incyte Corporation, Incyte Corporation
Urothelial Carcinoma
01/24
01/24
NCT05287113: Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
2
176
Europe, Canada, US, RoW
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Incyte Biosciences International Sàrl
Head and Neck Cancer
03/25
06/25
PERELI, NCT06389799: A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma

Recruiting
2
33
Europe
Pemigatinib, Retifanlimab
Lund University Hospital
Dedifferentiated Liposarcoma
12/27
12/28
NCT06160206: Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Recruiting
2
134
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
11/26
11/30
MERCURY, NCT05594290: Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery

Recruiting
2
36
Europe
Retifanlimab, Cisplatin, Etoposide
Gruppo Oncologico del Nord-Ovest
Merkel Cell Carcinoma
11/25
11/26
NCT04116073: INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Completed
2
25
US
INCMGA00012 (PD-1 antibody), MGA012
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI)
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
08/24
12/24
RiLEY, NCT05239182: 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Active, not recruiting
2
32
US
9-ING-41, Retifanlimab, INCMGA00012, Gemcitabine, Abraxane
Anwaar Saeed, Actuate Therapeutics Inc., Incyte Corporation
Pancreatic Adenocarcinoma
12/24
06/25
TORNADO, NCT04968106: Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas

Recruiting
2
66
Europe
Doxorubicin, Ifosfamide, INCMGA00012, Retifanlimab
Institut Bergonié, Incyte Biosciences International Sàrl
Resectable Sarcoma
03/25
10/27
POD1UM-204, NCT04463771 / 2020-000496-20: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Active, not recruiting
2
206
Europe, US, RoW
retifanlimab, INCMGA00012, epacadostat, pemigatinib, INCAGN02385, INCAGN02390
Incyte Corporation, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Endometrial Cancer
04/26
07/26
AuspiCiOus, NCT05177133: Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer

Recruiting
2
25
Europe
Capecitabine, Xeloda, Oxaliplatin, Oxaliplatin Accord, Retifanlimab, INCMGA00012
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Incyte Corporation
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
05/25
11/29
NCT04438824: Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Active, not recruiting
2
42
US
INCMGA00012, Palbociclib
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Well-differentiated/Dedifferentiated Liposarcoma
06/26
06/26
NCT05345002: All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Recruiting
2
55
US
Retifanlimab, All-trans retinoic acid
Stephen Bagley, MD, MSCE, Incyte Corporation, University of Pennsylvania
Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma
06/26
06/27
TRICK-MCC, NCT06056895: Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Active, not recruiting
2
12
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Tuparstobart, Anti-LAG-3 Monoclonal Antibody INCAGN02385, Anti-LAG3 Monoclonal Antibody INCAGN02385, INCAGN 02385, INCAGN 2385, INCAGN02385, INCAGN2385, Verzistobart, Anti-TIM-3 Monoclonal Antibody INCAGN02390, INCAGN 02390, INCAGN-02390, INCAGN02390
University of Washington, Incyte Corporation
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
01/27
04/27
CP-MGC018-01, NCT03729596 / 2018-003555-38: MGC018 With or Without MGA012 in Advanced Solid Tumors

Terminated
1/2
143
Europe, US, RoW
vobramitamab duocarmazine, MGC018
MacroGenics, MacroGenics, Inc.
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer
03/23
03/23
2018-003555-38: Study of MGC018 Alone and in Combination with MGA012 in Patients with Advanced Solid Tumors

Not yet recruiting
1/2
193
Europe
MGC018, MGA012 (INCMGA00012), NA, Concentrate for solution for infusion
MacroGenics, Inc., MacroGenics, Inc.
Advanced Solid Tumors, Advanced cancer disease, Diseases [C] - Cancer [C04]
 
 
NCT06149481: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Recruiting
1/2
60
US
Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803, SX-682
National Cancer Institute (NCI)
Metastatic Colorectal Cancer
10/25
10/28
NCT06320405: Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Recruiting
1/2
38
US
Axatilimab, Anti-M-CSFR Monoclonal Antibody SNDX-6352, SNDX 6352, SNDX-6352, SNDX6352, UCB6352, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz
OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
04/27
04/29
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Anticipated efficiency data in combination with Bria-IMT
Dec 2018 - Dec 2018: Anticipated efficiency data in combination with Bria-IMT
Checkmark Safety data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
11/25
11/28
SANTANA-225, NCT06939036: Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC ( )

Recruiting
1/2
50
US
225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab
Ariceum Therapeutics GmbH
Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
08/26
12/26
NCT06873789: A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

Recruiting
1/2
322
US
INCB177054, Retifanlimab
Incyte Corporation
Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
10/28
10/28
NCT04370704: Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Active, not recruiting
1/2
61
US, RoW
INCAGN02385, INCAGN02390, INCMGA00012.
Incyte Corporation
Melanoma
08/25
08/25
NCT04577014: Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Recruiting
1/2
98
US
Retifanlimab, INCMGA00012, Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
09/26
09/26
NCT06959537: A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Not yet recruiting
1/2
24
US
Cyclophosphamide, Axatilimab (SNDX-6352), Retifanlimab
M.D. Anderson Cancer Center
Breast Cancer
01/27
01/29
NCT05455697: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Recruiting
1/2
35
US
Bone Marrow Biopsy, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cyclostine, Cytophosphane, Cytoxan, Fosfaseron, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, 14-Hydroxydaunomycin, 23214-92-8, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Prednisone, Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltra, Econosone, Lisacort, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Predicor, Predicorten, Prednicort, Prednilonga, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Retifanlimab, 2226345-85-1, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Tafasitamab, 1422527-84-1, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain,, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, 22-Oxovincaleukoblastine, 57-22-7, LEUROCRISTINE, VCR, Vincrystine, Bone Marrow Aspiration, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Fludeoxyglucose F-18, 105851-17-0, 18FDG, Positron Emission Tomography, Medical Imaging, PET Scan, Positron Emission Tomography Scan, Computed Tomography, CAT Scan, Computed Axial Tomography, CT SCAN, Biospecimen Collection, Biological Sample Collection, Polatuzumab Vedotin, Antibody-Drug Conjugate DCDS4501A, Polivy
University of Washington
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
01/27
07/27
INCMGA 0012-102, NCT03589651: INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Completed
1b
83
US
Retifanlimab, Epacadostat, INCB024360, INCMGA00012, INCB050465
Incyte Corporation
Unresectable or Metastatic Solid Tumors
11/22
11/22
NCT04799431: Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

Withdrawn
1
12
NA
Neoantigen Vaccine with Poly-ICLC adjuvant, Hiltonol® (Poly-ICLC), Retifanlimab, INCMGA00012; MGA012
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI)
Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
05/23
05/23
NCT03522142: A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Active, not recruiting
1
84
Europe, US
INCB081776, INCMGA00012, retifanlimab
Incyte Corporation
Advanced Solid Tumors
09/25
09/25
NCT04470024: Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Recruiting
1
56
US
INCAGN01876, INCMGA00012, DPV-001
Providence Health & Services
Cancer of the Head and Neck
12/25
12/27
NCT06179160: A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Recruiting
1
466
Europe, Canada, Japan, US, RoW
INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX
Incyte Corporation
Solid Tumors
01/27
01/27
NCT04580485: INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Completed
1
54
Europe, US
INCB106385, INCMGA00012
Incyte Corporation
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
01/24
01/24
NCT04989387: Study of INCA 0186 in Subjects With Advanced Solid Tumors

Completed
1
57
Europe, US
INCA00186, Retifanlimab, INCB106385
Incyte Corporation
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
09/24
09/24
POD1UM-101, NCT03059823: A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Checkmark Data from PODIUM-101 trial for endometrial cancer at SITC 2021
Nov 2021 - Nov 2021: Data from PODIUM-101 trial for endometrial cancer at SITC 2021
Checkmark First patient dosed in China for 2L MSI-H endometrial cancer
Nov 2020 - Nov 2020: First patient dosed in China for 2L MSI-H endometrial cancer
Checkmark Preliminary data from PODIUM-101 trial for endometrial cancer at SITC 2020
More
Completed
1
325
Europe, US, RoW
retifanlimab, INCMGA0012
Incyte Corporation
Locally Advanced Solid Tumors, Metastatic Solid Tumors
05/24
05/24
NCT06290622: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Withdrawn
1
18
NA
Retifanlimab, INCAGN02385, INCAGN02390
University of Alabama at Birmingham
Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular
06/26
01/28
NCT05743595: Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Recruiting
1
12
US
Personalized Neoantigen DNA vaccine, Retifanlimab, INCMGA00012, MGA012, TDS-IM v 2.0 electroporation device
Washington University School of Medicine, Incyte Corporation, PapiVax Biotech, Inc., The Foundation for Barnes-Jewish Hospital
Unmethylated Glioblastoma
01/26
10/28
NCT05440942: Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Completed
1
28
US
Trametinib, GSK1120212, TMT212-NXA, Mekinist, Ruxolitinib, INCB018424, INC424, Retifanlimab, INCMGA00012
Peter Hosein, MD, Incyte Corporation, Novartis Pharmaceuticals, University of Miami Sylvester Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma
05/25
05/25
RiLEY, NCT06896188: 9-ING-41 Combined with Retifanlimab, Plus Modified FOLFIRINOX for Patients with Advanced Pancreatic Adenocarcinoma

Not yet recruiting
1
12
US
Retifanlimab, ZYNYZ, Chemotherapy, 9-ING-41, Elraglusib
Anwaar Saeed, Actuate Therapeutics Inc., Incyte Corporation
Pancreatic Adenocarcinoma
05/27
12/28
NCT05083754: Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Recruiting
1
50
US
Retifanlimab, INCMGA00012, Temozolomide, Radiation Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Glioblastoma Multiforme
01/26
01/27
NCT06910137: An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

Available
N/A
NA
retifanlimab, INCMGA00012
Incyte Corporation
Squamous Cell Carcinoma of the Anal Canal
 
 
lorigerlimab (MGD019) / MacroGenics
NCT06730347: A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Recruiting
2
60
Canada, US, RoW
Lorigerlimab, MGD019
MacroGenics
Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer
02/27
08/27
TRACTION, NCT05475171: Triage of Advanced Cervical Cancer Through Immunotherapy Induction

Recruiting
2
40
US
Lorigerlimab, MGD019
M.D. Anderson Cancer Center, MacroGenics
Metastatic Cancer, Cervical Cancer
06/26
06/26
LORIKEET, NCT05848011: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
154
Europe, US, RoW
lorigerlimab, MGD019, docetaxel, Taxotere®, Prednisone
MacroGenics
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
09/26
09/27
NCT03761017: MGD019 DART® Protein in Unresectable/Metastatic Cancer

Completed
1
162
Europe, US, RoW
Lorigerlimab, MGD019
MacroGenics
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer, Advanced Cancer, Solid Tumor, Adult
08/24
01/25
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
07/25
10/25
vobramitamab duocarmazine (MGC018) / MacroGenics
MGC018-SCLC, NCT06227546: MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

Recruiting
2
17
US
MGC018
Georgetown University, MacroGenics
Extensive-stage Small-cell Lung Cancer
05/25
05/26
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
MGD014 / MacroGenics
NCT05261191: A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Completed
1
17
US
MGD020, MGD014
MacroGenics, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
05/24
05/24
izeltabart tapatansine (IMGC936) / MacroGenics, AbbVie
2021-002264-41: First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors Estudio del medicamento IMGC936 (primera vez que se prueba en personas) en pacientes con tumores sólidos avanzados

Not yet recruiting
2
250
Europe
IMGC936, IMGC936, Solution for infusion
ImmunoGen, Inc., ImmunoGen, Inc.
Advanced Solid Tumors Tumores sólidos avanzados, Advanced Solid Tumors Tumores sólidos avanzados, Diseases [C] - Cancer [C04]
 
 
NCT04622774 / 2021-002264-41: First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

Completed
1/2
56
Europe, US
IMGC936
ImmunoGen, Inc., MacroGenics
Advanced Solid Tumor
12/23
12/23
MGD024 / MacroGenics, Gilead
CP-MGD024-01, NCT05362773: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Recruiting
1
130
US
MGD024
MacroGenics
Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia
11/26
05/27
MGC026 / MacroGenics
NCT06242470: A Study of MGC026 in Participants With Advanced Solid Tumors

Recruiting
1
250
Europe, US, RoW
MGC026 Dose Escalation, MGC026 Dose for Expansion
MacroGenics
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)
05/28
10/28
IL13Rα2xCD3 bispecific DART / MacroGenics
No trials found
MGD020 / MacroGenics
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tzield (teplizumab-mzwv) / Sanofi
PETITE-T1D, NCT05757713: Teplizumab in Pediatric Stage 2 Type 1 Diabetes

Active, not recruiting
4
20
US
teplizumab
Provention Bio, a Sanofi Company
Diabetes Mellitus, Type 1
08/26
08/26
PROTECT, NCT03875729 / 2018-004926-26: Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Completed
3
328
Europe, Canada, US, RoW
teplizumab, Placebo
Provention Bio, Inc.
Type 1 Diabetes Mellitus
05/23
05/23
2013-002248-98: Preventing Diabetes with an Antibody in Relatives at Risk for the Disease

Ongoing
2
170
Europe, RoW
Anti-CD3 mAb, MGA031, Infusion
TrialNet Coordinating Center, TrialNet Coordinating Center University of South Florida, TRAILNET COORDINATING CENTER AT THE UNIVERSITY OF SOUTH FLORIDA, National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Diabetes and Digestive and
Anti-CD3 monoclonal antibody is to be used for the prevention of type 1 diabetes mellitus in relatives at risk for developing the disease., Type 1 Diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT04270942: At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

Completed
2
6
US
teplizumab 1 mg/mL, PRV-031, Tzield
Provention Bio, a Sanofi Company
Diabetes Mellitus, Type 1
01/24
01/24
KIBOU-T1D, NCT06791291: Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

Recruiting
2
10
Japan
Teplizumab, SAR446681, TZIELD
Sanofi
Type 1 Diabetes Mellitus
03/28
03/28
2017-002871-24: A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-onset Type 1 Diabetes Mellitus (T1D)

Not yet recruiting
1/2
48
Europe
AG019, Teplizumab, Gastro-resistant capsule, hard, Solution for infusion
Intrexon T1D Partners, LLC (IT1D), IT1D
Recent-onset Type 1 Diabetes mellitus (T1D), Recent-onset Type 1 Diabetes mellitus (T1D), Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
GLP-TEP, NCT06338553: GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

Recruiting
1
24
US
Semaglutide (Rybelsus®), Placebo
Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes
03/27
03/27
NCT06481904: Registry for Stage 2 Type 1 Diabetes

Recruiting
N/A
200
US
TZIELD (teplizumab-mzwv)
Sanofi
Type 1 Diabetes
01/37
01/37
TEPLI-REAL, NCT06892002: Description of Patients With Type 1 Diabetes Treated With Teplizumab

Recruiting
N/A
100
US
Teplizumab
Sanofi
Type 1 Diabetes
07/25
07/25
NCT04598893 / 2020-002798-92: Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

Active, not recruiting
N/A
188
Europe, Canada, US, RoW
Teplizumab, Placebo
Provention Bio, a Sanofi Company
Diabetes Mellitus, Type 1
11/26
11/26
Margenza (margetuximab-cmkb) / TerSera Therap
2019-004699-21: Study of Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in HER2-Positive Gastric or Gastroesophageal Junction Cancer

Not yet recruiting
2/3
860
Europe, RoW
Margetuximab, INCMGA00012, MGD013, Trastuzumab, MGAH22, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Herceptin
MacroGenics, Inc., MACROGENICS, INC., MacroGenics, Inc., Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator),  Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator), Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator)
Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer, Gastric Cancer or Gastroesophageal Junction Cancer, Diseases [C] - Cancer [C04]
 
 
MAHOGANY, NCT04082364 / 2019-004699-21: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Checkmark Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Sep 2021 - Sep 2021: Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Checkmark Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Sep 2021 - Sep 2021: Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Hourglass Sep 2020 - Mar 2021 : Completion of enrollment of module A of MAHOGANY trial
More
Completed
2/3
82
Europe, US, RoW
margetuximab, MGAH22, Margenza®, Retifanlimab, MGA012, INCMGA00012, Tebotelimab, MGD013, Trastuzumab, Herceptin, Chemotherapy
MacroGenics, Zai Lab (Shanghai) Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
01/24
03/25
NCT04262804: A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Active, not recruiting
2
123
RoW
Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine), Chosen Chemotherapy (Vinorelbine ), Chosen Chemotherapy (Gemcitabine )
Zai Lab (Shanghai) Co., Ltd.
Breast Cancer Metastatic
09/21
12/23
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
10/24
07/27
NCT03219268: A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Checkmark Data from trial for DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for DLBCL at ASH 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Nov 2020 - Nov 2020: Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at ASCO 2020
More
Completed
1
277
Europe, US, RoW
tebotelimab 1 mg, MGD013, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab, MGAH22, Margenza
MacroGenics
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
02/23
02/23
PRV-3279 / Sanofi
PREVAIL-2, NCT05087628: PRV-3279-2a Trial in Systemic Lupus

Terminated
2
28
US, RoW
PRV-3279, SAR446811, Placebo
Provention Bio, a Sanofi Company
Systemic Lupus Erythematosus
05/24
06/24
enoblituzumab (MGA271) / MacroGenics
NCT02923180: Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Checkmark Safety and clinical activity from trial for prostate cancer at ASCO 2022
Jun 2022 - Jun 2022: Safety and clinical activity from trial for prostate cancer at ASCO 2022
Active, not recruiting
2
33
US
Enoblituzumab, MGA271
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics
Prostate Cancer
08/20
07/25
NCT05338580: Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Withdrawn
2
160
RoW
TJ271 Injection in Combination with Pembrolizumab
TJ Biopharma Co., Ltd.
First-line Non-small-cell Lung Cancer, First-line Urothelial Carcinoma, Second-line Urothelial Carcinoma, Second-line Melanoma
12/23
12/23
HEAT, NCT06014255: Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Recruiting
2
219
US
Enoblituzumab, MGA271, Standard of Care
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics
Prostate Cancer
03/29
03/29
NCT05708924: MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Terminated
1
1
US
FT538, Enoblituzumab, RES242, MGA271
Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI)
Cancer, Solid Tumor, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
08/24
08/24
flotetuzumab (MGD006) / MacroGenics
NCT04582864: Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Terminated
2
11
US
Flotetuzumab, MGD006, Donor lymphocyte infusion, DLI
Washington University School of Medicine, MacroGenics, National Cancer Institute (NCI)
Relapsed Acute Myeloid Leukemia
03/24
07/24
PEPN1812, NCT04158739: Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

Active, not recruiting
1
16
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Flotetuzumab, CD123 x CD3 DART Bi-Specific Antibody MGD006, CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody MGD006, MGD006, RES234, S80880
Children's Oncology Group, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
09/22
09/25
NCT04681105: Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Active, not recruiting
1
13
US
Acetaminophen, APAP, Paracetamol, Tylenol, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Diphenhydramine, FAR 90X2, PM 255, Probedryl, Rigidyl, S51, Syntedril, Flotetuzumab, CD123 x CD3 DART Bi-Specific Antibody MGD006, CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody MGD006, MGD006, RES234, S80880, Ibuprofen, (.+ -.)-p-Isobutylhydratropic acid, Advil, Motrin, p-Isobutylhydratropic acid, Ranitidine
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
05/26
05/26
NCT05506956: Post-transplant Flotetuzumab for AML

Completed
1
3
US
Flotetuzumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics, National Cancer Institute (NCI)
Leukemia, Myeloid, Acute
06/24
06/24
NCT04678466: Flotetuzumab Expanded Access Program

No Longer Available
N/A
NA
flotetuzumab, MGD006
MacroGenics
Acute Myeloid Leukemia, AML, AML, Adult Recurrent
 
 
Zynyz (retifanlimab-dlwr) / Incyte
POD1UM-304, NCT04205812 / 2019-003372-39: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Active, not recruiting
3
583
Europe, US, RoW
Retifanlimab, INCMGA00012, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel
Incyte Corporation, Zai Lab (Shanghai) Co., Ltd.
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
12/23
08/26
POD1UM-303, NCT04472429 / 2020-000826-24: Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (/InterAACT 2).

Hourglass Dec 2024 - Dec 2024 : sBLA submission for SCAC
Active, not recruiting
3
308
Europe, Japan, US, RoW
carboplatin, paclitaxel, retifanlimab, INCMGA00012
Incyte Corporation
Squamous Cell Carcinoma of the Anal Canal
04/24
03/26
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
01/26
06/26
2021-001181-38: Study on the treatment of patients with gastroesophageal cancer with chemotherapy and immunotherapy based on a non-functioning DNA mismatch repair mechanism in the tumour cells Onderzoek naar de behandeling van patiënten met maag-/slokdarmkanker met chemotherapie en immunotherapie op basis van een niet werkend DNA mismatch herstel mechanisme in de tumorcellen

Not yet recruiting
2
25
Europe
Retifanlimab, INCMGA00012, Solution for infusion
Academic Medical Center, Incyte
Gastroesophageal cancer Oesophagus- en maagcarcinoom, Gastroesophageal cancer Slokdarm- en maagkanker, Diseases [C] - Cancer [C04]
 
 
2020-002244-23: An Open-Label, Randomized, Phase 2, Study of Various Therapies for Participants With Muscle-Invasive bladder cancer who are not eligible for Cisplatin or Refuse Cisplatin Therapy and are having bladder removal (Optimus) Studio generale in aperto, randomizzato, di fase 2 per valutare varie terapie per partecipanti con carcinoma muscolo-invasivo della vescica che sono non idonei al cisplatino o rifiutano la terapia con cisplatino e si sottopongono rimozione della vescica (Optimus)

Not yet recruiting
2
45
Europe
Epacadostat, Retifanlimab, [INCB024360], [INCMGA00012], Tablet, Solution for infusion
INCYTE CORPORATION, Incyte Corporation
Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy Carcinoma uroteliale muscolo-invasivo della vescica non idoneo al cisplatino o che rifiuta la terapia con cisplatino e si sottopone a cistectomia radicale, Muscle-Invasive Bladder cancer Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and having bladder removal Carcinoma muscolo-invasivo della vescica non idoneo al cisplatino o che rifiuta la terapia con cisplatino e con rimozione della vescica, Diseases [C] - Cancer [C04]
 
 
2021-001085-37: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Chimiothérapie néo-adjuvante plus retifanlimab (INCMGA00012)chez les patients porteurs de sarcomes rétropéritoneaux sélectionnés : une étude randomisée de phase II.

Not yet recruiting
2
66
Europe
Retifanlimab, DOXORUBICIN, HOLOXAN, INCMGA00012, Solution for infusion, Powder for infusion, DOXORUBICIN, HOLOXAN (Ifosfamide)
Institut Bergonié, Incyte Biosciences International Sarl
retroperitoneal sarcomas sarcomes rétropéritonéaux, retroperitoneal sarcomas sarcomes rétropéritonéaux, Diseases [C] - Cancer [C04]
 
 
2018-002070-51: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Not yet recruiting
2
81
Europe, RoW
INCMGA00012, Solution for infusion
Incyte Corporation, Incyte Corporation
Squamous Carcinoma of the Anal Canal, Squamous Carcinoma of the Anal Canal, Diseases [C] - Cancer [C04]
 
 
POD1UM-201, NCT03599713 / 2018-001627-39: A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma

Checkmark Data from PODIUM-201 trial for metastatic merkel cell carcinoma at SITC 2021
Nov 2021 - Nov 2021: Data from PODIUM-201 trial for metastatic merkel cell carcinoma at SITC 2021
Checkmark Data from POD1UM-201 trial in Merkel cell carcinoma at ESMO 2020
Sep 2020 - Sep 2020: Data from POD1UM-201 trial in Merkel cell carcinoma at ESMO 2020
Completed
2
107
Europe, Canada, US, RoW
Retifanlimab, MGA012, INCMGA00012
Incyte Corporation
Metastatic Merkel Cell Carcinoma
01/22
06/24
2021-005775-39: A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Estudio an fase II, aleatorizado, doble ciego y multicéntrico de retifanlimab en combinación con INCAGN02385 e INCAGN02390 como tratamiento de primera línea en participantes con carcinoma escamoso de cabeza y cuello metastásico/recidivante .

Ongoing
2
162
Europe
Retifanlimab, INCMGA00012, INCAGN02385, INCAGN0290, Solution for infusion
Incyte Biosciences International Sarl, Incyte Biosciences International Sarl
In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN. En participantes con PD-L1 positivo y terapia sistémica R/M SCCHN sin tratamiento previo., In participants with biomarker positive and untreated advanced head and neck cancer En participantes con biomarcadores positivos y con cancer de cabeza y cuello avanzado no tratado., Diseases [C] - Cancer [C04]
 
 
NCT04225039: Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma

Active, not recruiting
2
39
US
INCMGA00012, PD-1 inhibitor, PD1, INCAGN01876, Anti-GITR agonist, GITR, SRS, stereotactic radiosurgery, Brain surgery
University of Pennsylvania, Incyte Corporation
Glioblastoma
09/22
06/25
2022-000601-27: Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surgery in patients with operable Merkel cell carcinoma Studio volto a testare l’attività di un ciclo di chemio-immunoterapia con retifanlimab associato a platino-etoposide e seguito da chirurgia nei pazienti con carcinoma a cellule di Merkel operabile

Not yet recruiting
2
36
Europe
RETIFANLIMAB, CISPLATINO, carboplatino, etoposide, [INCMGA00012], [CISPLATINO], [carboplatino], [etoposide], Concentrate for solution for infusion
Fondazione GONO, Incyte Biosciences International, Fondazione GONO Onlus
The disease under clinical investigation is represented by resectable Merkel Cell Carcinoma (MCC), stage IIA-III (according to the AJCC staging system 8th edition). The study will include patients with a disease amenable for radical surgery as defined by local or institutional surgical practices, based on multidisciplinary team assessment La malattia oggetto di studio clinico è rappresentata dal tumore a cellule di Merkel (MCC) resecabile, stadiato clinicamente secondo il sistema di stadiazione AJCC, ottava edizione, come stadio IIA-III. Il protocollo arruolerà pazienti candidabili a trattamento chirurgico radicale secondo quanto definito dalla pratica clinica locale ed istituzionale, in seguito a valutazione in ambito multidisciplinare, Merkel cell carcinoma without metastases in other organs and surgically resectable Carcinoma a cellule di Merkel senza metastasi in altri organi e asportabile chirurgicamente, Diseases [C] - Cancer [C04]
 
 
ORPHEUS, NCT04231981 / 2019-001172-11: Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma

Completed
2
18
Europe
Retifanlimab, INCMGA0012
MedSIR, Incyte Biosciences International Sàrl
Penile Cancer
02/22
08/22
IRENE, NCT04445844: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, Study

Checkmark Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Dec 2021 - Dec 2021: Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Active, not recruiting
2
25
US
Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012
Mridula George, MD, Incyte Corporation, Oncolytics Biotech, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
06/25
06/25
NCT04949191 / 2021-002207-36: The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Terminated
2
10
Europe, Japan, US
Pemigatinib, INCB054828, Retifanlimab, INCMGA0012, Pembrolizumab
Incyte Corporation, Incyte Corporation
Advanced Malignancies
04/24
04/24
RHAPSODY, NCT04494009: PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy

Active, not recruiting
2
110
RoW
INCMGA00012
Asan Medical Center
Esophageal Cancer
12/25
12/26
NCT03532295: Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Hourglass Jan 2019 - Jan 2019 : P2 trial in recurrent gliomas
Active, not recruiting
2
51
US
Epacadostat, Bevacizumab, Avastin, Radiation therapy, Peripheral blood draw, Retifanlimab, INCMGA00012
Washington University School of Medicine, Incyte Corporation
Glioma, Glioblastoma
07/24
04/26
NCT05359692: INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Withdrawn
2
47
US
INCAGN01876, retifanlimab
Incyte Biosciences International Sàrl
Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
04/24
01/25
Optimus, NCT04586244 / 2020-002244-23: An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Terminated
2
30
Europe, US
retifanlimab, epacadostat, INCAGN02385, INCAGN02390
Incyte Corporation, Incyte Corporation
Urothelial Carcinoma
01/24
01/24
NCT05287113: Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
2
176
Europe, Canada, US, RoW
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Incyte Biosciences International Sàrl
Head and Neck Cancer
03/25
06/25
PERELI, NCT06389799: A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma

Recruiting
2
33
Europe
Pemigatinib, Retifanlimab
Lund University Hospital
Dedifferentiated Liposarcoma
12/27
12/28
NCT06160206: Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Recruiting
2
134
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
11/26
11/30
MERCURY, NCT05594290: Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery

Recruiting
2
36
Europe
Retifanlimab, Cisplatin, Etoposide
Gruppo Oncologico del Nord-Ovest
Merkel Cell Carcinoma
11/25
11/26
NCT04116073: INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Completed
2
25
US
INCMGA00012 (PD-1 antibody), MGA012
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI)
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
08/24
12/24
RiLEY, NCT05239182: 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Active, not recruiting
2
32
US
9-ING-41, Retifanlimab, INCMGA00012, Gemcitabine, Abraxane
Anwaar Saeed, Actuate Therapeutics Inc., Incyte Corporation
Pancreatic Adenocarcinoma
12/24
06/25
TORNADO, NCT04968106: Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas

Recruiting
2
66
Europe
Doxorubicin, Ifosfamide, INCMGA00012, Retifanlimab
Institut Bergonié, Incyte Biosciences International Sàrl
Resectable Sarcoma
03/25
10/27
POD1UM-204, NCT04463771 / 2020-000496-20: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Active, not recruiting
2
206
Europe, US, RoW
retifanlimab, INCMGA00012, epacadostat, pemigatinib, INCAGN02385, INCAGN02390
Incyte Corporation, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Endometrial Cancer
04/26
07/26
AuspiCiOus, NCT05177133: Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer

Recruiting
2
25
Europe
Capecitabine, Xeloda, Oxaliplatin, Oxaliplatin Accord, Retifanlimab, INCMGA00012
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Incyte Corporation
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
05/25
11/29
NCT04438824: Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Active, not recruiting
2
42
US
INCMGA00012, Palbociclib
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Well-differentiated/Dedifferentiated Liposarcoma
06/26
06/26
NCT05345002: All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Recruiting
2
55
US
Retifanlimab, All-trans retinoic acid
Stephen Bagley, MD, MSCE, Incyte Corporation, University of Pennsylvania
Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma
06/26
06/27
TRICK-MCC, NCT06056895: Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Active, not recruiting
2
12
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Tuparstobart, Anti-LAG-3 Monoclonal Antibody INCAGN02385, Anti-LAG3 Monoclonal Antibody INCAGN02385, INCAGN 02385, INCAGN 2385, INCAGN02385, INCAGN2385, Verzistobart, Anti-TIM-3 Monoclonal Antibody INCAGN02390, INCAGN 02390, INCAGN-02390, INCAGN02390
University of Washington, Incyte Corporation
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
01/27
04/27
CP-MGC018-01, NCT03729596 / 2018-003555-38: MGC018 With or Without MGA012 in Advanced Solid Tumors

Terminated
1/2
143
Europe, US, RoW
vobramitamab duocarmazine, MGC018
MacroGenics, MacroGenics, Inc.
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer
03/23
03/23
2018-003555-38: Study of MGC018 Alone and in Combination with MGA012 in Patients with Advanced Solid Tumors

Not yet recruiting
1/2
193
Europe
MGC018, MGA012 (INCMGA00012), NA, Concentrate for solution for infusion
MacroGenics, Inc., MacroGenics, Inc.
Advanced Solid Tumors, Advanced cancer disease, Diseases [C] - Cancer [C04]
 
 
NCT06149481: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Recruiting
1/2
60
US
Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803, SX-682
National Cancer Institute (NCI)
Metastatic Colorectal Cancer
10/25
10/28
NCT06320405: Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Recruiting
1/2
38
US
Axatilimab, Anti-M-CSFR Monoclonal Antibody SNDX-6352, SNDX 6352, SNDX-6352, SNDX6352, UCB6352, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz
OHSU Knight Cancer Institute, Oregon Health and Science University, Incyte Corporation
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
04/27
04/29
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Anticipated efficiency data in combination with Bria-IMT
Dec 2018 - Dec 2018: Anticipated efficiency data in combination with Bria-IMT
Checkmark Safety data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
11/25
11/28
SANTANA-225, NCT06939036: Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC ( )

Recruiting
1/2
50
US
225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab
Ariceum Therapeutics GmbH
Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
08/26
12/26
NCT06873789: A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

Recruiting
1/2
322
US
INCB177054, Retifanlimab
Incyte Corporation
Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
10/28
10/28
NCT04370704: Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Active, not recruiting
1/2
61
US, RoW
INCAGN02385, INCAGN02390, INCMGA00012.
Incyte Corporation
Melanoma
08/25
08/25
NCT04577014: Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Recruiting
1/2
98
US
Retifanlimab, INCMGA00012, Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
09/26
09/26
NCT06959537: A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Not yet recruiting
1/2
24
US
Cyclophosphamide, Axatilimab (SNDX-6352), Retifanlimab
M.D. Anderson Cancer Center
Breast Cancer
01/27
01/29
NCT05455697: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Recruiting
1/2
35
US
Bone Marrow Biopsy, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cyclostine, Cytophosphane, Cytoxan, Fosfaseron, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, 14-Hydroxydaunomycin, 23214-92-8, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Prednisone, Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltra, Econosone, Lisacort, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Predicor, Predicorten, Prednicort, Prednilonga, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Retifanlimab, 2226345-85-1, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012, Retifanlimab-dlwr, Zynyz, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Tafasitamab, 1422527-84-1, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain,, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, 22-Oxovincaleukoblastine, 57-22-7, LEUROCRISTINE, VCR, Vincrystine, Bone Marrow Aspiration, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Fludeoxyglucose F-18, 105851-17-0, 18FDG, Positron Emission Tomography, Medical Imaging, PET Scan, Positron Emission Tomography Scan, Computed Tomography, CAT Scan, Computed Axial Tomography, CT SCAN, Biospecimen Collection, Biological Sample Collection, Polatuzumab Vedotin, Antibody-Drug Conjugate DCDS4501A, Polivy
University of Washington
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
01/27
07/27
INCMGA 0012-102, NCT03589651: INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Completed
1b
83
US
Retifanlimab, Epacadostat, INCB024360, INCMGA00012, INCB050465
Incyte Corporation
Unresectable or Metastatic Solid Tumors
11/22
11/22
NCT04799431: Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

Withdrawn
1
12
NA
Neoantigen Vaccine with Poly-ICLC adjuvant, Hiltonol® (Poly-ICLC), Retifanlimab, INCMGA00012; MGA012
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI)
Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
05/23
05/23
NCT03522142: A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Active, not recruiting
1
84
Europe, US
INCB081776, INCMGA00012, retifanlimab
Incyte Corporation
Advanced Solid Tumors
09/25
09/25
NCT04470024: Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Recruiting
1
56
US
INCAGN01876, INCMGA00012, DPV-001
Providence Health & Services
Cancer of the Head and Neck
12/25
12/27
NCT06179160: A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Recruiting
1
466
Europe, Canada, Japan, US, RoW
INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX
Incyte Corporation
Solid Tumors
01/27
01/27
NCT04580485: INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Completed
1
54
Europe, US
INCB106385, INCMGA00012
Incyte Corporation
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
01/24
01/24
NCT04989387: Study of INCA 0186 in Subjects With Advanced Solid Tumors

Completed
1
57
Europe, US
INCA00186, Retifanlimab, INCB106385
Incyte Corporation
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
09/24
09/24
POD1UM-101, NCT03059823: A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Checkmark Data from PODIUM-101 trial for endometrial cancer at SITC 2021
Nov 2021 - Nov 2021: Data from PODIUM-101 trial for endometrial cancer at SITC 2021
Checkmark First patient dosed in China for 2L MSI-H endometrial cancer
Nov 2020 - Nov 2020: First patient dosed in China for 2L MSI-H endometrial cancer
Checkmark Preliminary data from PODIUM-101 trial for endometrial cancer at SITC 2020
More
Completed
1
325
Europe, US, RoW
retifanlimab, INCMGA0012
Incyte Corporation
Locally Advanced Solid Tumors, Metastatic Solid Tumors
05/24
05/24
NCT06290622: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Withdrawn
1
18
NA
Retifanlimab, INCAGN02385, INCAGN02390
University of Alabama at Birmingham
Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular
06/26
01/28
NCT05743595: Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Recruiting
1
12
US
Personalized Neoantigen DNA vaccine, Retifanlimab, INCMGA00012, MGA012, TDS-IM v 2.0 electroporation device
Washington University School of Medicine, Incyte Corporation, PapiVax Biotech, Inc., The Foundation for Barnes-Jewish Hospital
Unmethylated Glioblastoma
01/26
10/28
NCT05440942: Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

Completed
1
28
US
Trametinib, GSK1120212, TMT212-NXA, Mekinist, Ruxolitinib, INCB018424, INC424, Retifanlimab, INCMGA00012
Peter Hosein, MD, Incyte Corporation, Novartis Pharmaceuticals, University of Miami Sylvester Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma
05/25
05/25
RiLEY, NCT06896188: 9-ING-41 Combined with Retifanlimab, Plus Modified FOLFIRINOX for Patients with Advanced Pancreatic Adenocarcinoma

Not yet recruiting
1
12
US
Retifanlimab, ZYNYZ, Chemotherapy, 9-ING-41, Elraglusib
Anwaar Saeed, Actuate Therapeutics Inc., Incyte Corporation
Pancreatic Adenocarcinoma
05/27
12/28
NCT05083754: Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Recruiting
1
50
US
Retifanlimab, INCMGA00012, Temozolomide, Radiation Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Glioblastoma Multiforme
01/26
01/27
NCT06910137: An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

Available
N/A
NA
retifanlimab, INCMGA00012
Incyte Corporation
Squamous Cell Carcinoma of the Anal Canal
 
 
lorigerlimab (MGD019) / MacroGenics
NCT06730347: A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Recruiting
2
60
Canada, US, RoW
Lorigerlimab, MGD019
MacroGenics
Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer
02/27
08/27
TRACTION, NCT05475171: Triage of Advanced Cervical Cancer Through Immunotherapy Induction

Recruiting
2
40
US
Lorigerlimab, MGD019
M.D. Anderson Cancer Center, MacroGenics
Metastatic Cancer, Cervical Cancer
06/26
06/26
LORIKEET, NCT05848011: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
154
Europe, US, RoW
lorigerlimab, MGD019, docetaxel, Taxotere®, Prednisone
MacroGenics
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
09/26
09/27
NCT03761017: MGD019 DART® Protein in Unresectable/Metastatic Cancer

Completed
1
162
Europe, US, RoW
Lorigerlimab, MGD019
MacroGenics
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer, Advanced Cancer, Solid Tumor, Adult
08/24
01/25
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
07/25
10/25
vobramitamab duocarmazine (MGC018) / MacroGenics
MGC018-SCLC, NCT06227546: MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

Recruiting
2
17
US
MGC018
Georgetown University, MacroGenics
Extensive-stage Small-cell Lung Cancer
05/25
05/26
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
MGD014 / MacroGenics
NCT05261191: A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Completed
1
17
US
MGD020, MGD014
MacroGenics, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
05/24
05/24
izeltabart tapatansine (IMGC936) / MacroGenics, AbbVie
2021-002264-41: First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors Estudio del medicamento IMGC936 (primera vez que se prueba en personas) en pacientes con tumores sólidos avanzados

Not yet recruiting
2
250
Europe
IMGC936, IMGC936, Solution for infusion
ImmunoGen, Inc., ImmunoGen, Inc.
Advanced Solid Tumors Tumores sólidos avanzados, Advanced Solid Tumors Tumores sólidos avanzados, Diseases [C] - Cancer [C04]
 
 
NCT04622774 / 2021-002264-41: First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

Completed
1/2
56
Europe, US
IMGC936
ImmunoGen, Inc., MacroGenics
Advanced Solid Tumor
12/23
12/23
MGD024 / MacroGenics, Gilead
CP-MGD024-01, NCT05362773: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Recruiting
1
130
US
MGD024
MacroGenics
Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia
11/26
05/27
MGC026 / MacroGenics
NCT06242470: A Study of MGC026 in Participants With Advanced Solid Tumors

Recruiting
1
250
Europe, US, RoW
MGC026 Dose Escalation, MGC026 Dose for Expansion
MacroGenics
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)
05/28
10/28
IL13Rα2xCD3 bispecific DART / MacroGenics
No trials found
MGD020 / MacroGenics
No trials found

Download Options